FDA De Novo – US: The EndoRotor® device is indicated to resect and remove necrotic tissue in symptomatic walled off pancreatic necrosis /walled off necrosis (WOPN/WON) after having undergone endoscopic ultrasound (EUS) guided drainage.
for Mucosectomy
FDA 510(k) – US: The EndoRotor® is intended for use in endoscopic procedures by a trained gastroenterologist to resect and remove tissue, not intended for biopsy, of the gastrointestinal (GI) system including post-endoscopic mucosal resection (EMR) tissue persistence with a scarred base and residual tissue from the peripheral margins following EMR.
Connect With Us on Social Media
For general support & conference inquiries
coo@innovativedigestivehealth.org
For exhibitor or sponsorship inquiries
coo@innovativedigestivehealth.org
For media or marketing inquiries
coo@innovativedigestivehealth.org
Innovative Digestive Health Education & Research Inc.
All Rights Reserved.
Medical Marketing & Website Partner